Kline & Specter Pc
Professional Services |
Law Firms
1525 LOCUST ST
Recent News About Kline & Specter Pc
View More
-
PHILADELPHIA (Legal Newsline) - Federal multidistrict litigation, a procedure intended to resolve mass-tort lawsuits fairly and efficiently, has mutated into an unethical moneymaking machine for lawyers that is badly in need of reform, a prominent plaintiff attorney says as he prepares to lobby for changes.
-
WASHINGTON – According to data just released by the U.S. Small Business Administration and Treasury Department, 73 Pennsylvania law firms received government loans of at least $1 million while dealing with the coronavirus pandemic, including some of the state’s most influential plaintiffs’ firms.
-
PHILADELPHIA – A Philadelphia man who suffered permanent brain damage after a laser probe broke off during surgery will be compensated by a medical device company for $12.75 million.
-
PHILADELPHIA – A lawsuit brought in a Philadelphia court says negligence on the part of Penn State University and Bright Horizons, the nation’s largest child care provider, led to alleged repeat incidents of molestation against a five year-old child by a daycare center’s former Assistant Director.
-
PHILADELPHIA – In stark contrast to the $8 billion punitive damages verdict reached this past fall, two Risperdal cases were dismissed through successful motions for summary judgment from Johnson & Johnson in Philadelphia courtrooms.
-
PHILADELPHIA – A Philadelphia judge has struck down an attempt to recuse him from future proceedings surrounding a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal.
-
PHILADELPHIA – Johnson & Johnson, which was recently hit with a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal in Philadelphia, has filed motions to set it aside and call for a retrial – in addition to calling for the presiding judge to recuse himself from the case moving forward, alleging improper conduct like high-fives and pictures with jurors.
-
PHILADELPHIA – Johnson & Johnson and its subsidiary Janssen Pharmaceuticals have called a Philadelphia jury’s gigantic verdict of $8 billion in punitive damages against it for alleged malice connected to the marketing of anti-psychotic drug Risperdal “grossly disproportionate” and “a violation of due process” and are seeking to immediately overturn it.
-
PHILADELPHIA – In an unprecedented conclusion to the first-ever punitive damages trial tied to Risperdal, a 12-person jury found Johnson & Johnson and its subsidiary Janssen Pharmaceuticals liable for allegedly knowing and consciously disregarding the potential of the drug to cause gynecomastia to patients like plaintiff Nicholas Murray, and rendered a staggering verdict of $8 billion.
-
PHILADELPHIA – Cross-examination of a Johnson & Johnson doctor in the Risperdal punitive damages trial continued on Tuesday, with the physician stating that despite a number of email messages between herself and a statistician, that she played no role in the reanalysis of the drug’s data in 2015.
-
PHILADELPHIA – A plaintiff attorney in the punitive damages trial for Risperdal argued Friday that an independent biostatistician who reviewed the drug’s data for a reanalysis conducted in 2015, was in fact a former consultant for Johnson & Johnson who had worked on other litigation the company was involved in.
-
PHILADELPHIA – Testimony in the punitive damages trial for Risperdal on Thursday turned to both a statistical reanalysis of original clinical trial data as well as a 2003 article on the drug, which plaintiff counsel quoted one of its own original authors referring to as both “despicable” and “the poster boy of bad behavior.”
-
PHILADELPHIA – In continuing testimony taken during the first punitive damages trial surrounding anti-psychotic drug Risperdal in Philadelphia, a doctor who worked for Johnson & Johnson and its subsidiary Janssen Pharmaceuticals testified that the elevated prolactin levels of some boys participating in the drug’s early clinical trials were relevant, but not concerning at that time.
-
PHILADELPHIA – In continuing testimony taken during the first punitive damages trial surrounding anti-psychotic drug Risperdal in Philadelphia, a Johnson & Johnson senior director said that the company and its subsidiary Janssen Pharmaceuticals were not responsible for attempting to “spin” information provided to the media about the medication.
-
PHILADELPHIA – Johnson & Johnson did not market anti-psychotic drug Risperdal off-label to pediatricians and pediatric psychologists prior to receiving Food & Drug Administration approval, according to a senior official testifying in a trial meant to determine if the pharmaceutical giant will be penalized with punitive damages.
-
PHILADELPHIA – Testimony in the Risperdal punitive damages trial continued Thursday with a former Food & Drug Administration commissioner who said Johnson & Johnson and its subsidiary Janssen Pharmaceuticals sought to promote use of Risperdal in children and adolescents, before it was given such approval – but the company maintains it was safe for that age group.
-
PHILADELPHIA – On the first day of a trial that could expose Johnson & Johnson to millions of dollars in punitive damages, the company moved for a mistrial after plaintiffs attorneys reminded jurors of its massive value but was denied.
-
PHILADELPHIA – A private Catholic school in Lower Gwynedd Township, its operators and sponsors have settled litigation brought by the parents of a seventh-grade female student who was allegedly sexually molested multiple times by one of the school’s now-former and convicted IT workers, both on and off-campus.
-
PHILADELPHIA – A Philadelphia judge who presided over a case where a Lancaster woman claimed she suffered permanent injuries to her genitalia after the installation of a pelvic mesh implant manufactured by Johnson & Johnson subsidiary Ethicon, Inc., is recommending the Superior Court of Pennsylvania affirm the action’s $41 million verdict on appeal.
-
HARRISBURG – According to the Supreme Court of Pennsylvania, it will not hear an appeal of the first Risperdal case to be decided in the hands of a Philadelphia jury and its $2.5 million verdict for the plaintiff will stand.
